565 related articles for article (PubMed ID: 29718739)
1. Emerging therapeutic targets for treatment of leishmaniasis.
Sundar S; Singh B
Expert Opin Ther Targets; 2018 Jun; 22(6):467-486. PubMed ID: 29718739
[TBL] [Abstract][Full Text] [Related]
2. Glycobiology of the Leishmania parasite and emerging targets for antileishmanial drug discovery.
Chandra S; Ruhela D; Deb A; Vishwakarma RA
Expert Opin Ther Targets; 2010 Jul; 14(7):739-57. PubMed ID: 20536412
[TBL] [Abstract][Full Text] [Related]
3. Assay development in leishmaniasis drug discovery: a comprehensive review.
Zulfiqar B; Avery VM
Expert Opin Drug Discov; 2022 Feb; 17(2):151-166. PubMed ID: 34818139
[TBL] [Abstract][Full Text] [Related]
4. Protease inhibitors in potential drug development for Leishmaniasis.
Das P; Alam MN; Paik D; Karmakar K; De T; Chakraborti T
Indian J Biochem Biophys; 2013 Oct; 50(5):363-76. PubMed ID: 24772958
[TBL] [Abstract][Full Text] [Related]
5. Leishmaniasis drug discovery: recent progress and challenges in assay development.
Zulfiqar B; Shelper TB; Avery VM
Drug Discov Today; 2017 Oct; 22(10):1516-1531. PubMed ID: 28647378
[TBL] [Abstract][Full Text] [Related]
6. Need for sustainable approaches in antileishmanial drug discovery.
Hendrickx S; Caljon G; Maes L
Parasitol Res; 2019 Oct; 118(10):2743-2752. PubMed ID: 31473855
[TBL] [Abstract][Full Text] [Related]
7. Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis.
Alcântara LM; Ferreira TCS; Gadelha FR; Miguel DC
Int J Parasitol Drugs Drug Resist; 2018 Dec; 8(3):430-439. PubMed ID: 30293058
[TBL] [Abstract][Full Text] [Related]
8. Potential therapeutic targets and the role of technology in developing novel antileishmanial drugs.
Rajasekaran R; Chen YP
Drug Discov Today; 2015 Aug; 20(8):958-68. PubMed ID: 25936844
[TBL] [Abstract][Full Text] [Related]
9. Promising therapeutic targets for antileishmanial drugs.
Werbovetz KA
Expert Opin Ther Targets; 2002 Aug; 6(4):407-22. PubMed ID: 12223057
[TBL] [Abstract][Full Text] [Related]
10. Rational approaches for drug designing against leishmaniasis.
Shukla AK; Singh BK; Patra S; Dubey VK
Appl Biochem Biotechnol; 2010 Apr; 160(8):2208-18. PubMed ID: 19756413
[TBL] [Abstract][Full Text] [Related]
11. Exploiting knowledge on pharmacodynamics-pharmacokinetics for accelerated anti-leishmanial drug discovery/development.
Sundar S; Agrawal N; Singh B
Expert Opin Drug Metab Toxicol; 2019 Jul; 15(7):595-612. PubMed ID: 31174439
[No Abstract] [Full Text] [Related]
12. Current treatment and drug discovery against Leishmania spp. and Plasmodium spp.: a review.
Cruz AK; de Toledo JS; Falade M; Terrão MC; Kamchonwongpaisan S; Kyle DE; Uthaipibull C
Curr Drug Targets; 2009 Mar; 10(3):178-92. PubMed ID: 19275555
[TBL] [Abstract][Full Text] [Related]
13. Drug resistance in leishmaniasis.
Croft SL; Sundar S; Fairlamb AH
Clin Microbiol Rev; 2006 Jan; 19(1):111-26. PubMed ID: 16418526
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy of leishmaniasis: present challenges.
Uliana SRB; Trinconi CT; Coelho AC
Parasitology; 2018 Apr; 145(4):464-480. PubMed ID: 28103966
[TBL] [Abstract][Full Text] [Related]
15. Treatment of leishmaniasis: a review and assessment of recent research.
Elmahallawy EK; Agil A
Curr Pharm Des; 2015; 21(17):2259-75. PubMed ID: 25543123
[TBL] [Abstract][Full Text] [Related]
16. Targeting pteridine reductase 1 and dihydrofolate reductase: the old is a new trend for leishmaniasis drug discovery.
das Neves GM; Kagami LP; Gonçalves IL; Eifler-Lima VL
Future Med Chem; 2019 Aug; 11(16):2107-2130. PubMed ID: 31370699
[TBL] [Abstract][Full Text] [Related]
17. An Overview on Target-Based Drug Design against Kinetoplastid Protozoan Infections: Human African Trypanosomiasis, Chagas Disease and Leishmaniases.
Kourbeli V; Chontzopoulou E; Moschovou K; Pavlos D; Mavromoustakos T; Papanastasiou IP
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361781
[TBL] [Abstract][Full Text] [Related]
18. Limitations of Current Therapeutic Options, Possible Drug Targets and Scope of Natural Products in Control of Leishmaniasis.
Tiwari N; Gedda MR; Tiwari VK; Singh SP; Singh RK
Mini Rev Med Chem; 2018; 18(1):26-41. PubMed ID: 28443518
[TBL] [Abstract][Full Text] [Related]
19. The pharmacology of leishmaniasis.
Balaña-Fouce R; Reguera RM; Cubría JC; Ordóñez D
Gen Pharmacol; 1998 Apr; 30(4):435-43. PubMed ID: 9580315
[TBL] [Abstract][Full Text] [Related]
20. Novel Synthetic Approaches for Bisnaphthalimidopropyl (BNIP) Derivatives as Potential Anti-Parasitic Agents for the Treatment of Leishmaniasis.
Keskin E; Ucisik MH; Sucu BO; Guzel M
Molecules; 2019 Dec; 24(24):. PubMed ID: 31888250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
